Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007

Raffini, Leslie; Huang, Yuanjie; Witmer, Char; Feudtner, Chris

doi:10.1542/peds.2009-0768

Cited by 704 publications

(643 citation statements)

References 14 publications

Supporting

Mentioning

577

Contrasting

Unclassified

Order By: Relevance

“…Random, retrospective chart review was done by compiling a list of pediatric inpatient admissions. from a retrospective study 12 from 2001 to 2007 indicate that the annual rates have increased by 70% to 58 cases per 10 000 hospital admissions seen in all pediatric age groups. Although pediatric rates pale in comparison to the annual 200 000 to 600 000 estimated adult rates published in the white paper from the American Public Health Association, 13 the morbidity and mortality associated with them are as significant.…”

Section: Design Sample and Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Early Recognition of Pediatric Venous Thromboembolism: A Risk-Assessment Tool

Prentiss

2012

American Journal of Critical Care

View full text Add to dashboard Cite

BackgroundThe incidence of venous thromboembolism in children has increased dramatically, with most cases occurring in children with cancer, surgery, trauma, congenital heart disease, and systemic lupus erythematosus. Early assessment of risk factors present in children would minimize morbidity and mortality from these events. Objectives To evaluate the reliability and validity of a tool for assessing risk for venous thromboembolism in children. Methods The tool was developed after a review of the literature with assessment of content validity by a multidisciplinary team of experts. Patients' charts were reviewed retrospectively to establish reliability and validity of the tool. A P value less than .05 was considered statistically significant. Results Thirty-five charts were assessed for tool validity and were found to be statistically significant for all 3 risk score assessment categories. Logistic regression was used to assess 1001 patients' charts for internal consistency, which was found to be high (χ 2 5 [n = 1001] = 100.6, P < .001). Results indicated that most patients at risk for venous thromboembolism were between the ages of 13 and 17 years, with females having more than 7 times greater risk than males. Conclusions Descriptive statistics show that the assessment tool displays strong reliability and validity. Results validated a significant relationship between the risk score and the incidence of venous thromboembolism. Findings suggest that use of the assessment tool could significantly reduce adverse outcomes associated with venous thromboembolism in children. Notice to CE enrollees:A closed-book, multiple-choice examination following this article tests your under standing of the following objectives:1. Identify factors associated with increased risk for development of venous thromboembolism (VTE) in pediatric patients. 2. Describe study findings regarding the relationship between the total score on the risk assessment tool and the incidence of VTE in pediatric patients. 3. Discuss opportunities for future research related to VTE in pediatric patients.

show abstract

Section: Design Sample and Proceduresmentioning

confidence: 99%

“…12 More recent studies describe the mortality rate for patients with a VTE diagnosis as 8%, compared with 1% for other hospital diagnoses during the same period. The mean length of stay for patients with a diagnosis of VTE was 28 days compared with 6 days for patients admitted to the hospital for other reasons.…”

Section: Mortality and Morbiditymentioning

confidence: 99%

Early Recognition of Pediatric Venous Thromboembolism: A Risk-Assessment Tool

Prentiss

2012

American Journal of Critical Care

View full text Add to dashboard Cite

show abstract

“…Это обусловлено такими механиз-мами, как повреждение эндотелия и активация ткане-вого фактора, дисрегуляция системы гемостаза (акти-вация естественных прокоагулянтов и ингибирование фибринолитической системы), прокоагулянтный эф-фект провоспалительных цитокинов (интерлейкин 1b) и ростовых факторов (VEGF), механическая компрес-сия сосудов [7,8]. Кроме того, к потенциальным фак-торам, увеличивающим риск тромбоэмболических осложнений у детей со ЗНО, могут относиться следу-ющие [3,7,8] Согласно исследованию по определению особен-ностей течения ВТ у детей с саркомами, к указанным факторам риска добавляется иммобилизация, что харак-терно для пациентов со ЗНО. У 4 пациентов с тромбо-эмболией легочной артерии были обнаружены анти-фосфолипидные антитела.…”

Section: обзор литературыunclassified

Portal vein thrombosis in a patient with a malignant rhabdoid tumor of the liver (Case report)

Наумова¹

2015

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

“…In addition, chronic conditions with interim disease flares such as in inflammatory disorders (eg, systemic lupus erythematosus, bowel disorders, systemic sclerosis, or vasculopathies), infections (eg, infective endocarditis or bone infections), and nephrotic syndrome can be accompanied by intermittent prothrombotic periods. Lastly, acquired risk factors are typically exemplified by the presence of central venous catheters 1, 2, 4, 6, 8, 13, 14, 15…”

Section: Introductionmentioning

confidence: 99%

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

Luciani

Albisetti

Biss

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

BackgroundAnticoagulant therapy for venous thromboembolism (VTE) in children is largely based on treatment recommendations for adults. However, differences in both physiology (ie, renal maturation and drug excretion) and developmental hemostasis must be considered when treating children, as such differences could affect dose appropriateness, safety and efficacy.ObjectivesTo address these concerns, a study was designed to evaluate the safety of dabigatran etexilate in children requiring secondary thrombus prevention in whom an initial VTE was associated with an identified risk factor that persisted after the acute VTE treatment period. We report herein the rationale and design of the study.Patients/MethodsThis phase 3, open‐label, single‐arm, multicenter, multinational, prospective cohort study will be conducted in ≥100 children aged 0 to <18 years at ~100 specialist sites worldwide. Children will be treated with dabigatran etexilate for 12 months, or for a shorter duration if their identified VTE risk factor resolves, as per current American College of Chest Physicians recommendations. A nomogram will be used to determine starting doses for each patient.ResultsThe primary outcomes of the study will be VTE recurrence, bleeding events, overall mortality, and VTE‐related mortality. Secondary outcomes will include occurrence of post‐thrombotic syndrome, the pharmacokinetics of dabigatran, and the need for dose adjustments during treatment. Data on adverse events during the study will also be collected.ConclusionThis study will evaluate the safety of dabigatran etexilate for the secondary prevention of VTE in children, in addition to providing further data to guide pediatric dosing with dabigatran.

show abstract

Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007

Abstract: This multicenter study demonstrates a dramatic increase in the diagnosis of VTE at children's hospitals from 2001 to 2007.

Cited by 704 publications

References 14 publications

Early Recognition of Pediatric Venous Thromboembolism: A Risk-Assessment Tool

Early Recognition of Pediatric Venous Thromboembolism: A Risk-Assessment Tool

Portal vein thrombosis in a patient with a malignant rhabdoid tumor of the liver (Case report)

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

Contact Info

Product

Resources

About